复方苦参注射液联合TP化疗方案治疗中晚期食管癌患者的效果

Effects of Compound Kushen injection combined with TP chemotherapy in treatment of patients with advanced esophageal cancer

目的:观察复方苦参注射液联合TP化疗方案治疗中晚期食管癌患者的效果。方法:选取2019年1月至2023年1月该院收治的78例中晚期食管癌患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各39例。对照组采用TP化疗方案治疗,研究组在对照组基础上联合复方苦参注射液治疗,21 d为1个疗程,两组均连续治疗4个疗程。比较两组临床疗效,治疗前后肿瘤标志物[鳞状细胞癌相关抗原(SCC-Ag)、癌胚抗原(CEA)、高迁移率族蛋白B1(HMGB1)]水平、T细胞亚群指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平,以及不良反应发生率。结果:研究组疾病控制率(DCR)为94.87%(37/39),高于对照组的79.49%(31/39),差异有统计学意义(P<0.05);治疗后,研究组CEA、SCC-Ag、HMGB1水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05);两组白细胞减少、肝肾功能损害、血小板减少、胃肠道不适等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:复方苦参注射液联合TP化疗方案治疗中晚期食管癌患者可提高DCR,降低肿瘤标志物水平,调节T细胞亚群指标水平,效果优于单纯TP化疗方案治疗。

Objective:To observe effects of Compound Kushen injection combined with TP chemotherapy in treatment of patients with advanced esophageal cancer.Methods:A prospective study was conducted on 78 patients with advanced esophageal cancer admitted to the hospital from January 2019 to January 2023.They were divided into study group and control group according to the random number table method,39 cases in each.The control group was treated with TP chemotherapy regimen,while the study group was treated with compound Kushen injection on the basis of that of the control group.21 d was a course of treatment.Both groups were treated for 4 courses.The clinical efficacy,the levels of tumor markers[squamous cell carcinoma-associated antigen(SCC-Ag),carcinoembryonic antigen(CEA),high mobility group protein B1(HMGB1)],the T cell subset levels(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The disease control rate(DCR)of the study group was 94.87%(37/39),which was higher than 79.49%(31/39)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,SCC-Ag and HMGB1 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the study group were higher than those in the control group,the level of CD8^(+)was lower than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as leukopenia,liver and kidney dysfunction,thrombocytopenia,and gastrointestinal discomfort between the two groups(P>0.05).Conclusions:Compound Kushen injection combined with TP chemotherapy in the treatment of the patients with advanced esophageal cancer can improve the DCR,reduce the levels of tumor markers,and regulate the levels of T cell subsets.Moreover,it is superior to single TP chemotherapy regimen.